- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00544440
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
July 3, 2014 updated by: Janssen Research & Development, LLC
An Observational Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone Acetate (CB7630), in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
The purpose of this study is to investigate the effect of abiraterone acetate on levels of androgens and steroid metabolites in bone marrow plasma of patients with metastatic castration-resistant prostate cancer (CRPC).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a single-center, open-label (identity of assigned study drug will be known) study investigating the effect of abiraterone acetate on levels of testosterone and dihydrotestosterone (DHT) in bone marrow plasma of patients with metastatic CRPC and evaluating the difference in bone marrow androgen levels between patients with and without serum prostate specific antigen (PSA) decline.
Approximately 60 medically or surgically castrated male patients with metastatic CRPC will be enrolled.
The study will consist of screening, treatment, and follow-up periods.
Patients will be treated orally (by mouth) with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression.
Follow-up will continue until the patient dies, is lost to follow-up or withdraws informed consent.
Bone marrow aspirates will be collected at Week 1 (predose), Week 9, and the final study visit.
Safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
57
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Histologically proven adenocarcinoma of the prostate
- Eastern Cooperative Oncology Group (ECOG) performance status <=2 (Karnofsky Performance Status >=50%)
- Serum testosterone levels <50ng/ml
- Ongoing gonadal androgen deprivation therapy with luteinizing hormone-releasing hormone (LHRH) analogues or orchiectomy (patients, who have not had an orchiectomy, must be maintained on effective LHRH analogue therapy for the duration of the study)
- Progression of disease despite androgen ablation (either documented osseous or soft tissue metastatic disease progression or by prostate specific antigen [PSA] criteria progression)
- Progressive disease is defined by PSA evidence (PSA level of at least 5 ng/ml which has risen on at least 2 successive occasions, at least 2 weeks apart)
- Presence of metastatic bone disease
- Discontinue diethylstilbestrol or steroids treatment for >=4 weeks and for antiandrogens >6 weeks
- Antiandrogen withdrawal: patients who are receiving an antiandrogen as part of primary androgen ablation must demonstrate disease progression following discontinuation of antiandrogen (disease progression after antiandrogen withdrawal is defined as 2 consecutive rising PSA values, obtained at least 2 weeks apart, or documented osseous or soft tissue progression)
- For patients receiving flutamide, at least one of the PSA values must be obtained 4 weeks or more after flutamide discontinuation
- For patients receiving bicalutamide or nilutamide, at least one of the PSA values must be obtained 6 weeks or more after antiandrogen discontinuation
- Adequate adrenal function
- Laboratory values within protocol -defined parameters
- No evidence of chronic or acute disseminated intravascular coagulation or bleeding tendency and no angina at rest
- Agrees to protocol-defined use of effective contraception
Exclusion Criteria:
- Histologic variants other than adenocarcinoma in the primary tumor
- More then 2 different prior chemotherapeutic regimens for metastatic prostate cancer
- Abnormal liver function
- Therapy with other hormonal therapy, including any dose of megestrol acetate (Megace), Ketoconazole, finasteride (Proscar), dutasteride (Avodart) any herbal product known to decrease PSA levels (eg, Saw Palmetto and PC-SPES), or any systemic corticosteroid within 4 weeks prior to first dose of study drug
- Active infection or intercurrent illness that are not controlled
- Unstable angina, myocardial infarction within the previous 6 months, or use of ongoing maintenance therapy for life-threatening ventricular arrhythmia, uncontrolled hypertension, New York Heart Association (NYHA) Class III or IV congestive heart failure
- Prior radiation therapy completed <4 weeks or single fraction of palliative radiotherapy within 14 days prior to first dose of study drug
- Any currently active second malignancy, other than non-melanoma skin cancer
- Active psychiatric illnesses/social situations that would limit compliance with protocol requirements
- Active or uncontrolled autoimmune disease that may require corticosteroid therapy during study
- Severely compromised immunological state, including being positive for the human immunodeficiency virus (HIV)
- Acute or chronic hepatitis B or C
- Initiation of bisphosphonate therapy within 4 weeks prior to first dose of study drug
- Long QT syndrome or bundle branch block or hemiblock or other history of life-threatening arrhythmia (unless the patient has been effectively treated for it and is considered stable)
- Known brain metastasis
- History of pituitary or adrenal dysfunction
- History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
- Prior therapy with abiraterone acetate
- Any acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a NCI CTCAE (version 3) grade of <=1
- Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Abiraterone acetate plus prednisone
Patients will be treated orally with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression.
|
Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
Prednisone 5 mg tablet taken orally twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Detectable Bone Marrow Testosterone Level (>1 Picograms/Mililiter)
Time Frame: Baseline (predose Week 1 Day 1) and Week 8
|
Baseline (predose Week 1 Day 1) and Week 8
|
Number of Participants With Detectable Bone Marrow Dihydrotestosterone (DHT) Level (>9 Picograms/Mililiter)
Time Frame: Baseline (predose Week 1 Day 1) and Week 8
|
Baseline (predose Week 1 Day 1) and Week 8
|
Difference in Bone Marrow Testosterone Levels Between Participants With and Without Serum Prostate Specific Antigen Decline
Time Frame: Week 8
|
Week 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Change in Markers of Bone Metabolism
Time Frame: Week 8
|
Week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
October 15, 2007
First Submitted That Met QC Criteria
October 15, 2007
First Posted (Estimate)
October 16, 2007
Study Record Updates
Last Update Posted (Estimate)
July 17, 2014
Last Update Submitted That Met QC Criteria
July 3, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Prednisone
- Abiraterone Acetate
Other Study ID Numbers
- CR016906
- COU-AA-BMA (Other Identifier: Janssen Research & Development, LLC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Neoplasms
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Roswell Park Cancer InstituteUniversity of PittsburghCompletedProstate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of ProstateUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
DendreonCompletedProstate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of ProstateAustria, France, Netherlands, United Kingdom
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Institutes of Health (NIH)CompletedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIB Prostate CancerUnited States
-
National Cancer Institute (NCI)CompletedProstate Adenocarcinoma | Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Abiraterone acetate
-
Janssen Research & Development, LLCCompleted
-
Cougar Biotechnology, Inc.Completed
-
Cougar Biotechnology, Inc.Completed
-
Cougar Biotechnology, Inc.CompletedProstate NeoplasmsUnited Kingdom, United States
-
Janssen Research & Development, LLCCompletedHealthy ParticipantsUnited States
-
Assistance Publique - Hôpitaux de ParisJanssen, LPCompletedProstate CancerFrance
-
Memorial Sloan Kettering Cancer CenterUniversity of California, Los Angeles; Ferring Pharmaceuticals; Wayne State University and other collaboratorsCompleted
-
Janssen Research & Development, LLCCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedHealthy VolunteersChina
-
Cougar Biotechnology, Inc.Completed